Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

10.0%

3 terminated out of 30 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

17%

5 trials in Phase 3/4

Results Transparency

38%

8 of 21 completed with results

Key Signals

8 with results88% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (1)
P 2 (6)
P 3 (4)
P 4 (1)

Trial Status

Completed21
Unknown4
Terminated3
Recruiting1
Active Not Recruiting1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT00457587Active Not Recruiting

Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

NCT02019706Phase 2Recruiting

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

NCT00001452CompletedPrimary

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT07282223CompletedPrimary

Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism

NCT05633953CompletedPrimary

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

NCT03606408Phase 2CompletedPrimary

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

NCT03817840CompletedPrimary

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT02663609CompletedPrimary

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

NCT02297945Phase 3CompletedPrimary

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

NCT02468193Phase 2CompletedPrimary

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

NCT00361777CompletedPrimary

Diagnostic Performance of Screening Tests for Cushing s Syndrome

NCT02804750Phase 2CompletedPrimary

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT00422201Phase 2TerminatedPrimary

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT02922257CompletedPrimary

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

NCT02889224Not ApplicableCompletedPrimary

In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man

NCT00682084TerminatedPrimary

Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome

NCT00001453CompletedPrimary

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT02646553UnknownPrimary

Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.

NCT00088608Phase 2CompletedPrimary

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

NCT01504555UnknownPrimary

Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?

Scroll to load more

Research Network

Activity Timeline